The MYC/miR-17-92 axis in lymphoproliferative disorders: A common pathway with therapeutic potential
PDF | HTML | How to cite
Metrics: PDF 1834 views | HTML 2369 views | ?
Michele Dal Bo1,*, Riccardo Bomben1,*, Luis Hernández2, Valter Gattei1
1Clinical and Experimental Onco-Hematology Unit, Centro di Riferimento Oncologico, I.R.C.C.S., Aviano PN, Italy
2Department of Pathology, Hospital Clinic, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain
*These authors have contributed equally to this work
Michele Dal Bo, e-mail: [email protected]
Valter Gattei, e-mail: [email protected]
Keywords: miR-17-92 cluster, lymphoproliferative disorders, anti-miRNA based target therapy
Received: May 27, 2015 Accepted: July 10, 2015 Published: July 21, 2015
MicroRNAs (miRNAs) represent a class of small non-coding single-stranded RNA molecules acting as master regulators of gene expression post transcriptionally by inhibiting the translation or inducing the degradation of target messenger RNAs (mRNAs). In particular, the miR-17-92 cluster is widely expressed in many different cell types and is essential for many developmental and pathogenic processes. As a strong oncogene, miR-17-92 can regulate multiple cellular processes that favor malignant transformation, promoting cell survival, rapid cell proliferation, and increased angiogenesis. The miR-17-92 cluster has been reported to be involved in hematopoietic malignancies including diffuse large B-cell lymphoma, mantle cell lymphoma, Burkitt’s lymphoma, and chronic lymphocytic leukemia. Given the multiple and potent effects on cellular proliferation and apoptosis exerted by the miR-17-92 cluster, miRNAs belonging to the cluster surely represent attractive targets for cancer therapy also in the context of lymphoproliferative disorders. In the present review, we focus on the role of the miR-17-92 cluster in lymphoproliferative disorders, including diagnostic/prognostic implications, and on the potential applications of anti-miRNAs based therapies targeting miRNAs belonging to the cluster.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.